Printer Friendly

SRI INTERNATIONAL AND BIOSYM TECHNOLOGIES TO COLLABORATE ON MOLECULAR SIMULATION

 SRI INTERNATIONAL AND BIOSYM TECHNOLOGIES
 TO COLLABORATE ON MOLECULAR SIMULATION
 MENLO PARK, Calif., July 17 /PRNewswire/ -- SRI International and BIOSYM Technologies Inc. have announced that the two organizations will collaborate on molecular simulation and computer-aided drug design. The collaboration will combine SRI's research and development expertise with BIOSYM's software capabilities for molecular design.
 BIOSYM is providing software for use in SRI's research in rational drug design, synthetic polymers, catalysis, and organometallics. SRI's expertise in artificial intelligence, neural networks, and virtual reality will contribute to BIOSYM's development work. SRI, a leading developer of pharmaceuticals, uses medicinal chemistry, peptide and protein chemistry, biotechnology, and computer-aided drug design to discover new drugs. Through the collaboration, the companies intend to produce new tools to improve the R&D process.
 SRI has joined three of BIOSYM's consortia: Potential Energy Functions (PEFC), Polymer Project, and Catalysis and Sorption Project.
 The collaboration with PEFC will focus on development of tools useful in designing new molecules with desired properties. In the Polymer Project, SRI will work with BIOSYM on new software methods for predicting polymer properties. As part of the Catalysis and Sorption Project, SRI will collaborate on the development of tools for prediction of catalyst performance that will aid in the development of improved catalysts by computer-aided design. SRI's role will be to test the tools during development for reliability and ease of use and to suggest improvements.
 SRI and BIOSYM will also jointly provide contract research services where applicable.
 SRI International, based in Menlo Park, is one of the world's largest research, development, and consulting firms. BIOSYM, based in San Diego, is the preeminent supplier of molecular modeling tools to the scientific community.
 -0- 7/17/92
 /CONTACT: Catharine Way of SRI, 415-859-4464; or Christine Sheppard of BIOSYM, 619-458-9990/ CO: SRI International; BIOSYM Technologies Inc. ST: California IN: MTC SU:


MC-RM -- SJ001 -- 0234 07/17/92 12:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 17, 1992
Words:313
Previous Article:PARAMAX AWARDED U.S. AIR FORCE CONTRACT
Next Article:VIKONICS REPORTS YEAR-END RESULTS
Topics:


Related Articles
VERTEX PHARMACEUTICALS AND POLYGEN MOLECULAR SIMULATIONS SIGN STRATEGIC COLLABORATION AGREEMENT
GRC INTERNATIONAL APPOINTS FORMER SRI EXECUTIVE TO STRENGTHEN STRATEGIC PLANNING AND BUSINESS DEVELOPMENT ACTIVITIES
CORNING PLANS TO ACQUIRE BIOSYM TECHNOLOGIES
CORNING PLANS TO ACQUIRE BIOSYM TECHNOLOGIES
OXFORD MOLECULAR, UNIVERSITY OF CALIFORNIA SAN FRANCISCO FORM CO-DISTRIBUTION PARTNERSHIP FOR AMBER
CONVEX ANNOUNCES PARALLEL VERSION OF BIOSYM'S DISCOVER AVAILABLE FOR EXEMPLAR SYSTEMS
MSI Announces Sponsorship of Centre for Structural Biology at The University of York.
Bayer Joins MSI's Polymer and Pharmaceutical Development Consortia.
Molecular Simulations Redefines Distribution Strategy in Japan to Improve Growth Prospects and Customer Focus.
AstraZeneca Implements Global License of Accelrys Modeling Software.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters